FDA Asked to Review Drug Licenses for High-Alcohol OTC Beverages
What happened
The Ministry of Health and Welfare requested that the Food and Drug Administration (FDA) discuss the recategorization of certain beverages, including Paolyta B and Sanyo Whisbih. These drinks contain alcohol up to 10 percent and are currently marketed as over-the-counter (OTC) medicine. The Ministry asked the FDA to consider if the drug licenses for these products should be revoked. The concerns cited include the increased risk of oral cancer, esophageal cancer, liver cirrhosis, and serious workplace accidents due to alcohol impairment.
From taipeitimes.com
Why it matters
The review focuses on whether the drug licenses for these products should be revoked, which are currently marketed as containing traditional Chinese medicine and conventional medicine. The Ministry also requested the FDA bolster its public health promotion efforts regarding the products’ alcohol content.
From taipeitimes.com
Who's involved
- FDARegulatory body tasked with reviewing product licenses and public health warnings
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- FDASpeculative
The FDA could face pressure regarding the potential revocation of product drug licenses.
Keep exploring
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA is accused of failing to enforce safety regulations and operating under current rules without in-person oversight.
- Unregulated products are bypassing official government approval processes.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA guidance is driving the need for a safety assessment related to issues in Rockville.